Naslov
Left-right colon cancer and the effectiveness of targeted antibodies

Autori
Skelin, Marko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Skup
1. regionalni kongres internističke onkologije i 1. regionalni kongres onkološke farmacije

Mjesto i datum
Dubrovnik, Hrvatska, 2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Podatak o recenziji nije dostupan

Ključne riječi
left-right colon cancer ; targeted antibodies

Sažetak
Colon carcinoma is one of the most common malignant diseases. Therapeutic protocols used in its treatment are based on 5- fluorouracil in combination with oxaliplatin (adjuvant and metastatic treatment) and irinotecan (metastatic treatment). Apart from chemotherapy, for the treatment of metastatic carcinoma of the colon are used targeted antibodies that can be divided by their basic mechanism of action on the inhibitors of the epidermal growth factor receptor (EGFR) and the inhibitors of the vascular endothelial growth factor (anti- VEGF). EGFR inhibitors that are used in the Republic of Croatia are cetuximab and panitumumab. These two drugs showed no significant difference in their activity when tested in a head to head study, and therefore it’s considered that there is no significant difference between these two antibodies. Also it is important to highlight that the EGFR inhibitors are in use for the treatment of a wild-type RAS colorectal tumor while for the RAS mutated tumors is used anti- VEGF therapy, in particular bevacizumab. Difference in effectiveness regarding RAS mutation is obtained from randomized controlled studies (FIRE-3), which showed superiority of cetuximab compared to bevacizumab in a direct comparison. The superiority of cetuximab was based on the increase of overall survival compared to bevacizumab. However, recently published subanalysis of the two large studies including the FIRE-3, showed that the effectiveness of targeted antibodies depends of the primary location of the tumor. Tumors of the right side of colon have poorer survival compared to the tumors of the left side of colon and also had an unexpected difference in the efficacy of targeted antibodies. Bevacizumab showed a similar efficacy regardless the side of the colon, while cetuximab surprisingly showed the lack of efficacy compared to bevacizumab in a wildtype RAS tumor of the right side of the colon. The aim of this lecture will be to present the latest findings on the effectiveness of targeted antibodies in patients with metastatic carcinoma of the colon, depending on the primary location of the tumor.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA